| (a) |
Wiersinga W.M.
(1996) Advances in medical therapy of thyroid-associated ophthalmopathy.
Orbit, 15: 177-186. |
| (b) |
Perros P. et al.
(1995) Natural history of thyroid associated ophthalmopathy.
Clin. Endocrinol. (Oxf.), 42:45-50. |
| (c) |
Mourits M.Ph. et
al. (1997) Clinical activity score as a guide in the management
of patients with Graves' ophthalmopathy. Clin. Endocrinol. (Oxf.),
47: 9-14. |
| (d) |
Gerding M.N. et
al. (1999) Octreotide-scintigraphy is a disease-activity
parameter in Graves' ophthalmopathy. Clin. Endocrinol. (Oxf.),
50: 373-379. |
| (e) |
Colao A. et al.
(1998) Orbital scintigraphy with [111In-diethylenetriamine pentaacetic
acid acid-d-Phe1]-octreotide predicts the clinical response
to corticosteroid therapy in patients with Graves' ophthalmopathy. J.
Clin. Endocrinol. Metab., 83: 3790-3794. |
| (f) |
Gerding M.N. et al. (2000) Assessment
of disease activity in Graves' ophthalmopathy by orbital ultrasonography
and clinical parameters. Clin. Endocrinol. (Oxf.), 52: 641-646. |
| (g) |
Prummel M.F. et
al. (2001) The usefulness of quantitative orbital magnetic
resonance imaging in Graves' ophthalmopathy. Clin. Endocrinol.
(Oxf.), 54: 205-209. |
| (h) |
Wakelkamp I.M.M.J. et al. (2000)
Both Th1 and Th2 derived cytokines in serum are elevated in
Graves' ophthalmopathy. Clin. Exp. Immunol., 121: 453-457. |